Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BELZUTIFAN for Neoplasm: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 10 adverse event reports in the FDA FAERS database where BELZUTIFAN was used for Neoplasm.

Most Reported Side Effects for BELZUTIFAN

Side Effect Reports % Deaths Hosp.
Anaemia 154 15.1% 8 72
Fatigue 88 8.6% 0 16
Hypoxia 85 8.3% 7 65
Diarrhoea 42 4.1% 0 27
Death 41 4.0% 38 2
Dyspnoea 40 3.9% 0 26
Haemoglobin decreased 36 3.5% 0 6
Malignant neoplasm progression 36 3.5% 10 11
Off label use 35 3.4% 2 2
Oxygen saturation decreased 30 2.9% 0 14
Nausea 28 2.7% 0 14
Product dose omission issue 25 2.5% 0 3
Therapy interrupted 25 2.5% 0 11
Pneumonia 24 2.4% 3 22
No adverse event 22 2.2% 0 0

Other Indications for BELZUTIFAN

Renal cell carcinoma (291) Clear cell renal cell carcinoma (237) Renal cancer (186) Von hippel-lindau disease (55) Haemangioblastoma (28) Phakomatosis (17) Product used for unknown indication (12) Endometrial adenocarcinoma (11) Hepatocellular carcinoma (7) Adenocarcinoma pancreas (5)

Other Drugs Used for Neoplasm

BEVACIZUMAB (502) ATEZOLIZUMAB (404) CYCLOPHOSPHAMIDE (385) CARBOPLATIN (283) PACLITAXEL (267) NIVOLUMAB (219) OXALIPLATIN (185) PEMBROLIZUMAB (173) LENALIDOMIDE (171) DOXORUBICIN (150)

Related Pages

BELZUTIFAN Full Profile All Neoplasm Drugs BELZUTIFAN Demographics BELZUTIFAN Timeline